Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 415,924 shares, a growth of 47.4% from the December 31st total of 282,105 shares. Based on an average daily volume of 161,860 shares, the days-to-cover ratio is currently 2.6 days. Approximately 4.5% of the company’s stock are short sold. Approximately 4.5% of the company’s stock are short sold. Based on an average daily volume of 161,860 shares, the days-to-cover ratio is currently 2.6 days.

Vivos Therapeutics Price Performance

Shares of Vivos Therapeutics stock opened at $1.62 on Tuesday. The stock has a 50 day moving average of $2.04 and a 200 day moving average of $3.07. Vivos Therapeutics has a 12 month low of $1.56 and a 12 month high of $7.95. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. The firm has a market cap of $15.29 million, a PE ratio of -0.92 and a beta of 6.89.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. The company had revenue of $6.78 million for the quarter, compared to analysts’ expectations of $4.49 million. On average, research analysts expect that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Ascendiant Capital Markets dropped their price target on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd. Finally, HC Wainwright started coverage on Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.92.

Institutional Investors Weigh In On Vivos Therapeutics

Institutional investors have recently made changes to their positions in the company. Connective Capital Management LLC bought a new stake in Vivos Therapeutics in the third quarter worth about $620,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics in the second quarter worth approximately $220,000. Finally, XTX Topco Ltd bought a new position in shares of Vivos Therapeutics during the 2nd quarter worth $65,000. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.